Showing results (241-250 of 333) with videos related to
Sort By:
Pageof 34
Cancer Science|July 19, 2020
Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global studyTakashi Seto, Hidetoshi Hayashi, Miyako Satouchi, et al.Oncotarget|May 10, 2014
Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinomaHidetoshi Hayashi, Tokuzo Arao, Kazuko Matsumoto, et al.Cancer Science|May 29, 2018
ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naïve Japanese patients with EGFR mutation-positive non-small-cell lung cancerKoichi Azuma, Makoto Nishio, Hidetoshi Hayashi, et al.Cancer Research|January 13, 2025
Myeloid Cells Induce Infiltration and Activation of B Cells and CD4+ T Follicular Helper Cells to Sensitize Brain Metastases to Combination ImmunotherapyToshifumi Ninomiya, Naoya Kemmotsu, Fumiaki Mukohara, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2022
Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN StudyBenjamin J Solomon, Todd M Bauer, Sai-Hong Ignatius Ou, et al.The Journal of Clinical Investigation|October 30, 2019
U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activationKoji Haratani, Kimio Yonesaka, Shiki Takamura, et al.Molecular Cancer Therapeutics|September 26, 2014
MEK inhibitor for gastric cancer with MEK1 gene mutationsShunsuke Sogabe, Yosuke Togashi, Hiroaki Kato, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 4, 2009
Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG0401)Hiroyasu Kaneda, Isamu Okamoto, Hidetoshi Hayashi, et al.Molecular Carcinogenesis|February 27, 2016
Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapiesTakuro Mizukami, Yosuke Togashi, Saeko Naruki, et al.Medical Oncology (Northwood, London, England)|September 22, 2021
Docetaxel plus cisplatin in recurrent and/or metastatic non-squamous-cell head and neck cancer: a multicenter phase II trialYoshinori Imamura, Kaoru Tanaka, Naomi Kiyota, et al.Pageof 34